| Project/Area Number |
24701036
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
TANAKA Yuko 東京医科大学, 医学部, 助教 (70449130)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | multile myeloma / sphingosine-1 phosphate / fingolimod / sphingosine 1-phasphate / 多発性骨髄腫 / ABC294640 / sphingosine1phosphate / multiple myeloma |
|---|
| Research Abstract |
multiple myeloma (MM),which is one of B-lymphocyte neoplasma, is not curable disease in spite of establishing new theraputic strategy.Therefore it is necessary to develop more excellent treating for the disease.To that end, it is require to elucidating pathophysiology in a new beginning.In pathology of multiple myeloma, the role of sphingosine-1 phosphate(S1P) is not revealed yet. On the other hand the function of S1P for cell biology gradually becomes clear. S1P plays important role of cell proliferation, survival, apoptosis, and migration. Indeed S1P is known to be concerned with the cell proliferation and developing of malignant tumors. In this study we try to reveal the relevance with MM and S1P for developing new therapeutic strategy.
|
